Komori
P

PHC Holdings Corporation

6523Electrical Equipment and Precision InstrumentsMid cap
1,281JPY-10.4%
★ Watch (sign-up required)
Price history
¥1,281Latest-44.3%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group operates across the full range of medical devices, healthcare IT and drug-discovery support, centered on diabetes management, healthcare solutions, and diagnostics and life sciences. Its core business is the development, manufacture and sale of blood glucose monitoring systems, with operations in Japan and overseas. Across the PHC Group, products are sold to medical institutions and pharmacies in more than 90 countries. The Group also has overseas manufacturing subsidiaries and sells products in Japan on an OEM basis. It has established a structure designed to maximize synergies between segments.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 19
PER
26.48How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
3.8%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥168bnShare price × number of shares. The value of the entire company.
Equity ratio
31.2%The proportion of assets funded by money that does not have to be repaid.
Operating margin
11.5%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
3.7%The average annual growth in sales over the past three years.
What to watch next
Ramp-up of E1000 Dx (digital pathology) sales in Japan, including the number of adopting facilities, sales volume and recurring revenue
2H FY2026–FY2027Impact MediumLikelihood Medium
Expansion of LiCellGrow (automated cell-culture system) sales and progress in orders and installations
2H FY2026–FY2027Impact MediumLikelihood Medium
Impact on the revenue structure, earnings and cash flow of the transfer of the CGM (Eversense) sales business to Senseonics
FY2026 (impact following completion of the transfer)Impact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 79.6%
Listed holders 79.6%Everyone else 20.4%
KKR PHC INVESTMENT L.P. (standing proxy: Mitsubishi UFJ Bank)37.94%
MITSUI & CO.,LTD.14.68%
Mitsubishi Chemical Corporation9.72%
パナソニックホールディングス株式会社6.14%
The Master Trust Bank of Japan, Ltd. (Trust Account)3.48%
LCA 3 MOONSHOT LP（常任代理人 みずほ銀行決済営業部）2.07%
J.P. MORGAN SECURITIES PLC（常任代理人 JPモルガン証券）1.87%
BNY GCM CLIENT ACCOUNT JPRD AC ISG(FE-AC)1.51%
2 other listed holders2.15%
Who owns it
HolderOwnership (%)
KKR PHC INVESTMENT L.P. (standing proxy: Mitsubishi UFJ Bank)37.94
MITSUI & CO.,LTD.14.68
Mitsubishi Chemical Corporation9.72
パナソニックホールディングス株式会社6.14
The Master Trust Bank of Japan, Ltd. (Trust Account)3.48
LCA 3 MOONSHOT LP（常任代理人 みずほ銀行決済営業部）2.07
J.P. MORGAN SECURITIES PLC（常任代理人 JPモルガン証券）1.87
BNY GCM CLIENT ACCOUNT JPRD AC ISG(FE-AC)1.51
2 other listed holders2.15
This company's documents
Filings
Timely disclosures
Threads